Table 4.

Predictors of Metachronous Contralateral BC and Death As a Result of Any Cause

Characteristic	Contralateral BC			Death As a Result of Any Cause
	Adjusted HR	95% CI	P	Adjusted HR	95% CI	P
HL history
HL survivor	4.3	1.7 to 11.0	< .01	1.9	1.1 to 3.3	< .05
Sporadic BC	Reference			Reference
Stage
DCIS or stage I	Reference			Reference
Stages IIA-IV	0.8	0.3 to 2.6	NS	4.0	2.1 to 7.6	< .001
Unknown	1.1	0.2 to 6.5	NS	1.7	0.5 to 6.5	NS
Regional lymph node involvement
Negative	Reference			Reference
Positive	1.2	0.4 to 3.8	NS	1.1	0.6 to 2.0	NS
Unknown	1.4	0.5 to 4.2	NS	2.7	1.2 to 5.9	< .05
Type of surgery
Lumpectomy	Reference			Reference
Unilateral mastectomy	0.2	0.1 to 0.7	< .01	1.2	0.7 to 2.1	NS
Bilateral mastectomy	—	—	—	1.2	0.4 to 3.1	NS
Other/none/unknown	2.2	0.4 to 11.7	NS	3.5	1.0 to 12.2	< .05
Surgical margins
Negative	Reference			Reference
Positive	1.6	0.5 to 5.0	NS	2.4	1.3 to 4.4	< .01
Unknown	0.9	0.3 to 3.0	NS	1.5	0.8 to 2.9	NS
Any chemotherapy*
No	Reference			Reference
Yes	1.0	0.4 to 2.6	NS	1.6	0.8 to 2.8	NS
Any hormonal therapy*
No	Reference			Reference
Yes	1.2	0.5 to 3.2	NS	0.8	0.5 to 1.3	NS
Any radiation*
No	Reference			Reference
Yes	0.7	0.3 to 1.9	NS	0.9	0.5 to 1.5	NS
Method of detection
Screening mammogram	1.2	0.5 to 2.9	NS	0.5	0.3 to 0.8	< .05
Other	Reference			Reference
Menopausal status
Premenopausal	Reference			Reference
Peri- or postmenopausal	0.7	0.2 to 2.7	NS	2.8	1.2 to 6.4	< .05
Unknown	5.2	0.8 to 35.8	NS	1.6	0.8 to 3.4	NS
Family history of breast cancer
None	Reference			Reference
First-degree relative	2.7	1.1 to 6.4	< .05	0.9	0.5 to 1.6	NS
Unknown	2.0	0.5 to 7.2	NS	1.1	0.5 to 2.2	NS

Abbreviations: BC, breast cancer; DCIS, ductal carcinoma in situ; HL, Hodgkin's lymphoma; HR, hazard ratio; NS, not statistically significant.

^*Chemotherapy, hormonal therapy, or radiation therapy for treatment of breast cancer.